Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB) Meeting Abstract
| Authors: | Mora, J.; Chan, G. C. F.; Morgenstern, D. A.; Nysom, K.; Bear, M. K.; Dalby, L. W.; Lisby, S.; Kushner, B. H. |
| Abstract Title: | Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368300262 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.10543 |
| Notes: | Meeting Abstract: 10543 -- Source: Wos |
